Chronic myeloid leukaemia remission stability after tyrosine - kinase inhibitors therapy cessation: a review of literature
Introduction: Chronic myeloid leukaemia (CML) is a specific malignant disease as it can be managed by a long-term oral tyrosine-kinase inhibitors (TKIs) treatment. Routine practise in the management of CML includes continuation of TKIs therapy even after the patient achieves remision. Several trials...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University Hospital for Tumors
2021-01-01
|
| Series: | Libri Oncologici |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/389029 |